RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Zynerba Pharmaceuticals Net Income 2024

Zynerba Pharmaceuticals Net Income

-34.52 M USD

Zynerba Pharmaceuticals Dividend yield

Ticker

ZYNE

ISIN

US98986X1090

WKN

A14XCV

In 2024, Zynerba Pharmaceuticals's profit amounted to -34.52 M USD, a -25% increase from the -46.03 M USD profit recorded in the previous year.

The Zynerba Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2028e155.43
2027e86.38
2026e28.33
2025e-20.17
2024e-34.52
2023e-46.03
2022-35.04
2021-37.31
2020-51.34
2019-32.94
2018-39.91
2017-32.01
2016-23.39
2015-12.55
2014-5.76
2013-0.8
2012-0.99

Zynerba Pharmaceuticals Aktienanalyse

What does Zynerba Pharmaceuticals do?

Zynerba Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe central nervous system disorders. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. The history of Zynerba Pharmaceuticals dates back to the discovery by Dr. Magid Abou-Gharbia, who led a team of scientists that developed a method for transporting cannabinoids through the blood-brain barrier. This groundbreaking discovery led to the formation of Zynerba Pharmaceuticals with the goal of developing novel cannabinoid-based therapies. Zynerba Pharmaceuticals' business model is based on the development of medical compounds derived from the cannabis plant. These compounds, known as cannabinoids, have the potential to treat a variety of different conditions related to the central nervous system. The company's strategy is to deliver these compounds in the form of transdermal patches to ensure optimal dosage and absorption by the body. Zynerba Pharmaceuticals is divided into different divisions that focus on specific conditions. The company's main division is the development of therapies for epilepsy based on the cannabinoid Zygel. Zygel is a synthetic cannabinoid administered as a transdermal patch and has high bioavailability. The patch is applied to the skin and delivers a precise dosage of Zygel to reduce seizures in patients with various forms of epilepsy. In addition, Zynerba Pharmaceuticals is working on therapies for neuropsychiatric disorders such as Fragile X syndrome, autism spectrum disorders, and schizophrenia. The company has a promising development pipeline and is currently involved in various clinical trials. The company has achieved many milestones and formed important partnerships to support its innovative research and development. In 2019, Zynerba Pharmaceuticals partnered with the Japanese company Daiichi Sankyo to expand its development pipeline. In summary, Zynerba Pharmaceuticals Inc offers a promising business model for the development of therapies for severe central nervous system disorders based on cannabinoids. The company has a promising development pipeline and has already formed important partnerships to support its research and development. Zynerba Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Zynerba Pharmaceuticals's Profit Margins

The profit margins of Zynerba Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Zynerba Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Zynerba Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Zynerba Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Zynerba Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Zynerba Pharmaceuticals Stock

How much profit has Zynerba Pharmaceuticals made this year?

Zynerba Pharmaceuticals has made -34.52 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -25% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Zynerba Pharmaceuticals publish its earnings?

Zynerba Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Zynerba Pharmaceuticals?

The profits of Zynerba Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Zynerba Pharmaceuticals?

You can learn more about the earnings of Zynerba Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Zynerba Pharmaceuticals pay?

Over the past 12 months, Zynerba Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynerba Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Zynerba Pharmaceuticals?

The current dividend yield of Zynerba Pharmaceuticals is .

When does Zynerba Pharmaceuticals pay dividends?

Zynerba Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Zynerba Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zynerba Pharmaceuticals located?

Zynerba Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zynerba Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zynerba Pharmaceuticals from 5/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/18/2024.

When did Zynerba Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/18/2024.

What was the dividend of Zynerba Pharmaceuticals in the year 2023?

In the year 2023, Zynerba Pharmaceuticals distributed 0 USD as dividends.

In which currency does Zynerba Pharmaceuticals pay out the dividend?

The dividends of Zynerba Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zynerba Pharmaceuticals

Our stock analysis for Zynerba Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zynerba Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.